The UK government has unveiled new measures aimed at accelerating the development and commercialisation of medicines manufactured in space, with the potential to deliver more effective and longer-lasting treatments for patients.
The initiative is designed to provide greater regulatory clarity for companies developing pharmaceuticals in orbit, helping them move innovations from research conducted in microgravity to approved medicines available on Earth.
Scientists and manufacturers have increasingly explored the unique conditions of microgravity — an environment that cannot be replicated on Earth — to improve the way biologic drugs form and behave. Researchers believe this could enhance the quality, stability and performance of complex medicines, potentially improving treatments for cancer, rare diseases and other conditions.
The new framework forms part of the UK government’s £2bn Life Sciences Sector Plan and is intended to support the rapid growth of in-orbit manufacturing by giving industry clearer guidance on regulatory pathways.
The package of measures has been led by the UK Space Agency, working alongside the Medicines and Healthcare products Regulatory Agency, the Regulatory Innovation Office within the Department for Science, Innovation and Technology, and the Civil Aviation Authority.
Together, the organisations will provide a coordinated set of tools designed to support companies developing pharmaceuticals in orbit. These include new regulatory guidance, case studies to demonstrate potential pathways to approval, a regulatory sandbox environment for testing innovations, and stronger engagement with supply chains.
By clarifying the route from orbital research to patient access, the government hopes to encourage investment and accelerate the commercial development of space-enabled pharmaceuticals.
Liz Lloyd, the UK’s Space Minister, said the initiative would help remove barriers that have historically slowed the development of medicines manufactured beyond Earth.
“The UK is taking medical breakthroughs from orbit to patient – tackling the practical barriers that have held back commercial in-orbit manufacturing, from regulatory uncertainty to supply chain gaps,” she said.
David Willetts, chair of the UK Space Agency and the Regulatory Innovation Office, said the emerging field offered both economic and healthcare benefits.
“In-orbit manufacturing of pharmaceuticals represents a significant opportunity for the UK, combining the growth potential of our space sector with the promise of better treatments for patients,” he said.
“The UK Space Agency is committed to supporting the companies pioneering this work, from microgravity platform providers to biotech and pharmaceutical firms.”
Willetts added that clearer regulatory frameworks would help encourage investment in the sector.
“Setting out a clear adoption pathway with well-defined regulatory requirements gives investors and entrepreneurs the confidence they need to bring these innovations to market,” he said.
“The UK is open for business in space-enabled pharmaceuticals, with the ambition and capability to lead globally.”
The government believes that establishing clear regulatory pathways now could help position the UK as a global hub for in-orbit pharmaceutical manufacturing, while expanding future treatment options for patients.
For more articles like this, visit our Innovation channel
